


## Data Sheet

Product Name:	Daprodustat
Cat. No.:	HY-17608
CAS No.:	960539-70-2
Molecular Formula:	C <sub>19</sub> H <sub>27</sub> N <sub>3</sub> O <sub>6</sub>
Molecular Weight:	393.43
Target:	HIF/HIF Prolyl-Hydroxylase
Pathway:	Metabolic Enzyme/Protease
Solubility:	DMSO: < 6.8 mg/mL



### BIOLOGICAL ACTIVITY:

Daprodustat is an orally active **hypoxia-inducible factor prolyl hydroxylase** inhibitor being developed for treatment of anemia associated with chronic kidney disease.

**In Vitro:** GSK1278863 is an orally administered small-molecule PHI, and stimulates endogenous EPO synthesis and induce effective erythropoiesis<sup>[1]</sup>. GSK1278863 has been shown to increase erythropoietin levels, leading to increases in hemoglobin, hematocrit and red blood cell numbers<sup>[2]</sup>.

### References:

[1]. Brigandi RA, et al. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. *Am J Kidney Dis.* 2016 Jun;67(6):861-71.

[2]. Hara K, et al. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. *Drug Metab Pharmacokinet.* 2015 Dec;30(6):410-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA